Isabella Strickland, MD
Family Medicine · Huntsville, ALNPI 1346212362
Payments from drug & device makers
Across 155 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$520
- Novo Nordisk$490
- Astellas Pharma US Inc$241
- AstraZeneca$186
- Pfizer$174
- AbbVie$136
- plus $868 from 18 others
What the payments were for
- Food & beverage$2,615100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 30 | $520 |
| Novo Nordisk | 30 | $490 |
| Astellas Pharma US Inc | 14 | $241 |
| AstraZeneca | 11 | $186 |
| Pfizer | 11 | $174 |
| AbbVie(2 entities) | 7 | $136 |
| Kowa Pharmaceuticals America, Inc. | 7 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $101 |
| Eisai Inc. | 6 | $81 |
| Abbott | 4 | $81 |
| IBSA Pharma Inc. | 4 | $76 |
| Lilly USA, LLC | 4 | $73 |
| Amgen(2 entities) | 4 | $62 |
| Novartis | 3 | $58 |
| Merck | 3 | $44 |
| Bayer | 2 | $37 |
| Scilex Pharmaceuticals Inc. | 2 | $25 |
| Exact Sciences | 1 | $18 |
| Scynexis, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Phadia US Inc. | 1 | $12 |
How this compares
$2,615 in reported general payments places this provider in the 70th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 90 | $92,072 |
| MounjaroTirzepatide | 64 | $87,638 |
| EliquisApixaban | 54 | $40,567 |
| JardianceEmpagliflozin | 34 | $36,947 |
| LinzessLinaclotide | 40 | $29,889 |
| MyrbetriqMirabegron | 48 | $28,006 |
| TrulicityDulaglutide | 21 | $24,417 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $16,384 |
| Repatha SyringeEvolocumab | 19 | $9,101 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $8,536 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 73 | $7,442 |
| Levothyroxine Sodium | 553 | $6,196 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 155 | $5,633 |
| Metformin Hcl | 212 | $4,535 |
| Atorvastatin Calcium | 421 | $4,035 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $73 | $112,05685 claims |
| Novo NordiskOzempic | $490 | $92,07290 claims |
| PfizerEliquis | $174 | $40,56754 claims |
| AbbVieLinzess, Synthroid | $136 | $33,06896 claims |
| Astellas Pharma US IncMyrbetriq | $241 | $28,00648 claims |
| GSKTrelegy Ellipta | $520 | $16,38416 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $25 | $2,15615 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $122 | $1,96811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Huntsville
- Michael CarterHuntsville$3.4M
- Randle MiddletonHuntsville$3.3M
- Timothy HowardHuntsville$3M
- Edward WittHuntsville$321K
- Kathleen DupperHuntsville$210K
- Whitney TewHuntsville$114K
- Jeffrey GarberHuntsville$87K
- Daniel EnglertHuntsville$82K
- Jack EnglertHuntsville$37K
- Tobin FisherHuntsville$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.